相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients
Jaydeep K. Srimani et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Sex differences in outcomes in multiple myeloma
Benjamin A. Derman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Is PFS the Right Endpoint to Assess Outcome of Maintenance Studies in Multiple Myeloma? Results of a Patient Survey Highlight Quality-of-Life As an Equally Important Outcome Measure
Anna Fleischer et al.
BLOOD (2021)
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Heinz Ludwig et al.
LEUKEMIA & LYMPHOMA (2020)
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
Ioannis V. Kostopoulos et al.
FRONTIERS IN ONCOLOGY (2020)
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Rafael Alonso et al.
BLOOD ADVANCES (2020)
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C. Munshi et al.
BLOOD ADVANCES (2020)
Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial
Sara Bringhen et al.
BLOOD (2020)
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Neeraj Gupta et al.
CLINICAL PHARMACOKINETICS (2019)
Genomic Landscape of Sex Disparities in Multiple Myeloma
Susan Bal et al.
BLOOD (2019)
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Kyriaki Tzogani et al.
ESMO OPEN (2019)
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the ConnectA® MM Registry
Rafat Abonour et al.
ANNALS OF HEMATOLOGY (2018)
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
Neeraj Gupta et al.
TARGETED ONCOLOGY (2017)
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
Neeraj Gupta et al.
CLINICAL PHARMACOKINETICS (2017)
Maintenance therapy in multiple myeloma
Prerna Mewawalla et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
Neeraj Gupta et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
Neeraj Gupta et al.
INVESTIGATIONAL NEW DRUGS (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3
Wendy P. Battisti et al.
ANNALS OF INTERNAL MEDICINE (2015)
Telomerase-Mediated Repair of Induced DNA Breaks Leads to Increased Genomic Instability in Multiple Myeloma Cells: Possible Mechanism and Translational Significance
Jagannath Pal et al.
BLOOD (2014)
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig et al.
BLOOD (2012)
Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
Karthick Raja Muthu Raja et al.
PLOS ONE (2012)
Perls-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2004)
分享论文
